How to buy VistaGen Therapeutics stock
Learn how to easily invest in VistaGen Therapeutics stock.
VistaGen Therapeutics is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 32 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy VistaGen Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VTGN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
VistaGen Therapeutics stock price (NASDAQ: VTGN)Use our graph to track the performance of VTGN stocks over time.
VistaGen Therapeutics shares at a glance
|Latest market close||$5.19|
|52-week range||$1.62 - $13.05|
|50-day moving average||$4.49|
|200-day moving average||$4.26|
|Wall St. target price||$30.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-6.50|
Buy VistaGen Therapeutics stock from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy VistaGen Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
VistaGen Therapeutics price performance over time
|1 week (2023-09-15)||-12.77%|
|1 month (2023-08-22)||-9.74%|
|3 months (2023-06-22)||196.57%|
|6 months (2023-03-22)||3,233.33%|
|1 year (2022-09-22)||3,105.68%|
|2 years (2021-09-22)||85.36%|
|3 years (2020-09-22)||746.93%|
|5 years (2018-09-21)||284.44%|
VistaGen Therapeutics financials
|Operating margin TTM||12921.82%|
|Gross profit TTM||$-227,300|
|Return on assets TTM||-78.79%|
|Return on equity TTM||-175.33%|
|Market Capitalization||$53.2 million|
TTM: trailing 12 months
VistaGen Therapeutics share dividends
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
Have VistaGen Therapeutics's shares ever split?
VistaGen Therapeutics's shares were split on a 1:30 basis on 6 June 2023. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
VistaGen Therapeutics share price volatility
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $1.62 up to $13.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.4672. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics overview
Vistagen Therapeutics, Inc. , a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders.
Frequently asked questionsWhat percentage of VistaGen Therapeutics is owned by insiders or institutions?
Currently 0.788% of VistaGen Therapeutics shares are held by insiders and 11.438% by institutions. How many people work for VistaGen Therapeutics?
Latest data suggests 32 work at VistaGen Therapeutics. When does the fiscal year end for VistaGen Therapeutics?
VistaGen Therapeutics's fiscal year ends in March. Where is VistaGen Therapeutics based?
VistaGen Therapeutics's address is: 343 Allerton Avenue, South San Francisco, CA, United States, 94080 What is VistaGen Therapeutics's ISIN number?
VistaGen Therapeutics's international securities identification number is: US92840H2022 What is VistaGen Therapeutics's CUSIP number?
VistaGen Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92840H103
More guides on Finder
How to buy Discord stock when it goes public
Everything we know about the Discord IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
How to buy Tottenham Acquisition I stock
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
How to buy TotalEnergies stock
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
How to buy Thunder Bridge Acquisition stock
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
How to buy Switchback Energy Acquisition Corporation stock
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
How to buy Telefonica SA ADR stock
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
How to buy Faraday Future stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
How to buy Phoenix Tree stock
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
How to buy Innate Pharma stock
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Ask an Expert